Aptar Pharma pulled the trigger on a deal for Pharmaxis’ Orbital high payload dry powder inhaler technology, paying $2.5 million for a worldwide license with the same again to follow if it chooses to buy the system outright.
Aptar Pharma, a leader in drug delivery and active material science solutions and services, has acquired the worldwide rights to clinical stage drug developer Pharmaxis’ proprietary Orbital inhaler, a unique device designed to deliver high payload dry powder to the lungs.
SYDNEY, Nov. 9, 2021 /PRNewswire/ -- Clinical stage drug development company Pharmaxis Ltd (ASX: PXS) today announced that an Investigational New Drug application (IND) for a trial of PXS-5505 in hepatocellular carcinoma (HCC) patients has been cleared by the United States Food and Drug Administration (FDA). The IND was submitted by the University of Rochester Medical Center, New York State, following the positive pre-clinical results reported in August 2021 at the Americas Hepato-Pancreato-Biliary Association conference in Miami, USA. The trial design approved by the FDA calls for PXS-5505 to be added to current chemotherapy standard of care; combination of a PD-L1 inhibitor and an anti-VEGF drug as first line therapy in newly diagnosed patients with unresectable HCC carcinoma.
SYDNEY, Oct. 5, 2021 /PRNewswire/ -- Clinical stage drug development company Pharmaxis Ltd (ASX: PXS) today announced further positive results of data analysis from a phase 1c clinical trial (MF-101) studying its drug PXS-5505 in patients with the bone marrow cancer myelofibrosis for 28 days at three dosage levels.
SYDNEY, Aug. 31, 2021 /PRNewswire/ -- Pharmaxis (ASX: PXS) today announced that its novel topical drug treatment for scarring has delivered positive Phase 1 clinical trial results and will now advance to the next stage of development in patients. In a study of healthy volunteers led by renowned surgeon Prof Fiona Wood AM the Pharmaxis drug demonstrated good tolerability and full inhibition of the enzymes being targeted to prevent scarring.
Aptar Pharma, a global provider of drug delivery systems, services and active material science services, entered an agreement with Pharmaxis, a clinical stage drug developer, under which Aptar Pharma has the option to acquire the worldwide rights to Pharmaxis’ high payload dry powder inhaler, Orbital. Aptar will evaluate the commercial applications for the Orbital device and further develop the prototype device to meet unmet market needs. Pharmaxis retains the rights to devices containing Orbital intellectual property used to deliver inhaled mannitol.
Clinical stage drug development company Pharmaxis Ltd (ASX: PXS) today announced the first public presentation of data from a preclinical study of PXS-5505 in the liver cancer, cholangiocarcinoma (CCA) at the Americas Hepato-Pancreato-Biliary Association (AHBPA) conference in Miami, USA.
Clinical stage drug development company Pharmaxis (ASX: PXS) has announced the sale of the ndistribution rights in Australia, New Zealand and several Asian territories for its cystic fibrosis nproduct Bronchitol® and asthma diagnostic Aridol® to Bioimpact Pty Ltd, a wholly owned subsidiary nof BTC health Ltd (BTC Health). Pharmaxis will receive a distributor appointment fee of A$2 million nwithin 10 business days
Pharmaxis Ltd’s (ASX:PXS) Gary Phillips says first results from a three-stage phase 1c clinical trial (MF-101) studying a potential treatment for bone marrow cancer myelofibrosis, have demonstrated strong inhibition of target enzymes LOX and LOXL2 in patients. The study aims to demonstrate that PXS-5505 is safe and effective as a monotherapy in myelofibrosis patients who are intolerant, unresponsive or ineligible for treatment with approved JAK inhibitor drugs.
Clinical stage drug development company Pharmaxis Ltd (ASX: PXS) today announced it has completed dosing the first of three stages in its phase 1c clinical trial (MF?101) studying a potential new treatment for the bone marrow cancer myelofibrosis. The study’s safety monitoring committee that advises on the study progress, has given the green light to progress to the second dose level after reviewing factors including the safety and pharmacokinetic properties of PXS?5505 in myelofibrosis patients.